Filed Nov 10, 2026Period of report Nov 10, 20260001705477-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 10, 2026
Common StockF1F2
4,442
$45.427
$201.79K
6,495
Direct
Filing footnotes · 3
F1Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.
Filed Aug 14, 2026Period of report Aug 12, 20260001185829-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 12, 2026
Common StockF1F2
8,782
$43.6408
$383.25K
61,677
Direct
SaleAug 12, 2026
Common StockF1F3
8,276
$43.6582
$361.32K
53,401
Direct
SaleAug 12, 2026
Common StockF1F4
913
$44.33
$40.47K
52,488
Direct
Filing footnotes · 8
F1Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
F6Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F7Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
F81/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Filed Jul 2, 2026Period of report Jul 1, 20260001853529-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 1, 2026
Common StockF2
130,352
$39.406
$5.14M
94,203
Direct
SaleJul 1, 2026
Common StockF3
69,648
$39.4089
$2.74M
24,555
Direct
Filing footnotes · 5
F1Includes 107 shares purchased on November 15, 2025 and 1,048 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.905, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F41/48th of the shares subject to the option vest each month beginning on September 10, 2018, subject to the Reporting Person continuing as a service provider through each vest date.
F51/48th of the shares subject to the option vest each month beginning on July 27, 2017, subject to the Reporting Person continuing as a service provider through each vest date.
Filed May 5, 2026Period of report May 4, 20260001644087-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 5, 2026
Common StockF1F3
50,000
$38.568
$1.93M
4,367
Direct
SaleMay 4, 2026
Common StockF1F2
5,230
$31.2931
$163.66K
4,367
Direct
Filing footnotes · 4
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.72 to $31.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $39.96 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F41/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.
Filed Apr 2, 2026Period of report Apr 1, 20260001644087-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 1, 2026
Common StockF1F2
28,662
$32.3109
$926.10K
9,597
Direct
Filing footnotes · 3
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F31/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.
Filed Mar 31, 2026Period of report Mar 31, 20260001644087-26-000002
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 31, 2026
Common StockF1F2
21,338
$32.1168
$685.31K
9,597
Direct
Filing footnotes · 3
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F31/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.
Filed Mar 30, 2026Period of report Mar 27, 20260001644087-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 27, 2026
Common StockF1F2F3
9,623
$30.9778
$298.10K
16,332
Direct
SaleMar 27, 2026
Common StockF2
6,735
$30.9778
$208.64K
9,597
Direct
Filing footnotes · 3
F1The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares).
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
Filed Jan 23, 2026Period of report Jan 21, 20260001786966-26-000001
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJan 21, 2026
Common StockF1F2
13,690
$29.44
$403.03K
121,601
Direct
SaleJan 21, 2026
Common StockF1F2
17,236
$29.44
$507.43K
104,365
Direct
SaleJan 21, 2026
Common StockF1F2
7,605
$29.44
$223.89K
96,760
Direct
SaleJan 21, 2026
Common StockF1F2
10,463
$29.44
$308.03K
86,297
Direct
SaleJan 21, 2026
Common StockF1F2
66,477
$29.44
$1.96M
19,820
Direct
Filing footnotes · 2
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025.
F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.